VistaGen Therapeutics Company Presentation

www.vistagen.com 20 Treatment of Adjustment Disorder with Anxiety PART A exploratory Phase 2A open-label study protocol submitted to FDA under Coronavirus Treatment Acceleration Program (CTAP); protocol development discussions ongoing with FDA Division of Psychiatry Products PH94B Phase 2 Program for Adjustment Disorder Principal Investigator: Dr. Michael Liebowitz, Columbia University, New York PART A • Exploratory, open-label, single-site Phase 2A study in New York City • Target enrollment, 30 POTENTIAL PART B • Randomized, double-blind, placebo-controlled, multi-center U.S. Phase 2B study • Potential target enrollment, 150